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Abstract
Background: The effect of previous natural pandemic H1N1 (H1N1 pdm09) influenza infection on the immunogenicity
to subsequent inactivated influenza vaccination in children has not been well studied. We aimed to evaluate the effect
of H1N1 pdm09 natural infection and vaccination on the immunogenicity to subsequent 2010-2011 seasonal inactivated
influenza vaccination in children.
Methods: From October 2010 to May 2011, we conducted an open-label, multi-center study in children aged
6 months -18 years in Korea. We measured antibody titers with a hemagglutination-inhibition (HI) assay at baseline,
1 month, and 6 months after vaccination with trivalent split or subunit vaccines containing H1N1 pdm, A/H3N2, and B.
The subjects were classified into 4 groups depending on the presence of laboratory-confirmed H1N1 pdm09 infection
and/or vaccination in the 2009-2010 season; Group I: vaccination (-)/infection(-), Group II: vaccination (-)/infection(+),
Group III: vaccination (+)/infection(-), Group IV: vaccination (+)/infection(+).
Results: Among the subjects in group I, 47 subjects who had a baseline titer >1:10 were considered to have an
asymptomatic infection. They were included into the final group II (n = 80). We defined the new group II as the
infection-primed (IP) group and group III as the vaccine-primed (VP) group. Seroconversion rate (57.5 % vs 35.9 %,
p = 0.001), seroprotection rate at 6 months after vaccination (70.8 % vs 61.8 %, p = 0.032), and GMT at 1 month after
vaccination (129.9 vs 66.5, p = 0.002) were significantly higher in the IP group than in the VP group. In the 9–18 year-
old group, seroconversion rate and immunogenicity at 1 and 6 months were significantly higher in the IP group than
in the VP group. However in the 1–7 year-old age group, there was no significant difference between the two groups.
Conclusions: Previous H1N1 pdm09 infection appears to have positive effects on immunogenicity of subsequent
inactivated influenza vaccines against H1N1 pdm09 in older children.
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Background
After a worldwide pandemic influenza A H1N1(H1N1
pdm09) virus infection in 2009, seasonal influenza vaccines
contain the A/California/7/2009 (H1N1)-like strain.
Immunogenicity studies of pandemic H1N1 influenza
vaccines and seasonal influenza vaccines including the A/
California/7/2009 (H1N1)-like strain have been carried out
globally. Although the pandemic influenza vaccines played
some role in the elimination of H1N1 pdm09 influenza,
H1N1 pdm09 influenza natural infection may contribute
to the acquisition of herd immunity. The 2009 pandemic
infection provided an opportunity to study the influence of
natural infection on the immune responses. The evidence
of a higher immune response elicited by natural H1N1
pdm09 infection than by vaccination was reported [1]. Fur-
thermore, the longer duration of hemagglutination inhib-
ition (HI) antibody by natural H1N1 pdm09 infection
(mean lives of 11.8 months) than that by vaccination (mean
lives of 8.35 months) was demonstrated [2]. On the
contrary, most of the solid organ transplant recipients lack
long-term humoral and cellular immune responses to in-
fluenza virus even after natural H1N1 pdm09 infection [3].
After primary influenza virus infection, the persistence of
influenza virus-specific antibody-secreting cells and devel-
opment of B-cell memory have been reported. This is
probably the associated mechanism of long-lasting protec-
tion induced by natural infection [4].
Studies about the seroprevalence or immunogenicity
in children are important because children are supposed
to be the target and source of the spread of influenza
infection [5, 6]. In children, one post-pandemic study
compared the antibody titers against H1N1 pdm09 after
natural infection and vaccination and demonstrated that
vaccinated children exhibit lower HI titers compared to
children with H1N1 pdm09 infection [7]. In our previ-
ous study, we similarly demonstrated that the immune
response induced by natural H1N1 pdm09 infection was
superior to that induced by pandemic H1N1 vaccination
[8]. However, little is known about the effect of natural
influenza infection on immunogenicity to subsequent
inactivated influenza vaccination. We hypothesized that
priming by previous natural influenza infection would
have a more positive effect on the immunogenicity of
vaccination in the following year than priming by previ-
ous vaccination. In this study, we aimed to evaluate the
effect of H1N1 pdm09 natural infection and vaccination
on the immunogenicity to subsequent 2010–2011
seasonal inactivated influenza vaccination containing the
A/California/7/2009 (H1N1)-like strain in children.
Methods
Study subjects and questionnaire
From October 2010 to May 2011, we conducted an
observational, open-label, prospective study in children
at five hospitals located in Seoul and Gyeonggi Province
in Korea. Healthy children aged 6 months to 18 years
randomly received split or subunit vaccines according to
vaccine assignment to each hospital (3 hospitals adminis-
tered split vaccines and 2 hospitals administered subunit
vaccines). Information about H1N1 pdm09 vaccination
and laboratory-confirmed H1N1 pdm09 infection in the
2009–2010 season was obtained by a questionnaire. Con-
firmation of H1N1 pdm09 infection in that time period
was obtained by H1N1 pdm09-specific real-time reverse
transcriptase-polymerase chain reaction in most hospitals
in Korea. An influenza A-positive result from the rapid
antigen test in several subjects was also included
because > 95 % of influenza isolates were H1N1 pdm09
viruses in Korea [9]. Subjects were divided into 4 groups
depending on the presence of H1N1 pdm09 infection
and/or H1N1 pdm09 vaccination in the 2009–2010 season;
Group I: vaccination (-)/infection(-), Group II: vaccination
(-)/infection(+), Group III: vaccination (+)/infection(-),
Group IV: vaccination (+)/infection(+).
The demographic data were collected for analysis. Sub-
jects who had severe allergy to influenza vaccine, acute
febrile illness at the time of vaccination, received immuno-
suppressants including corticosteroids, history of transfu-
sion within 6 months, and any other conditions which
might interfere with the evaluation of the study were ex-
cluded. All subjects were observed for 30 min following
vaccine administration to check for immediate local and/
or systemic reactions. Parents/guardians were provided
with diary cards to record the occurrence of solicited local
reactions (pain, erythema, swelling), systemic symptoms
(fever/chill, headache, myalgia, malaise) and unsolicited
symptoms experienced during the first 7 days after vaccin-
ation. All adverse events (AEs) were reviewed during in-
terviews with parents/guardians at the scheduled study
visit on day 30 post-vaccination. Serious adverse events
(SAEs) that occurred during the study were reported to
the institutional review board (IRB). The study protocol
was approved by the IRB of Korea Cancer Center Hospital
(K-1001-001-013) and the IRB of each hospital, and
written informed consent was obtained from parents of all
subjects before participation in the study.
Vaccines
Two kinds of vaccines were used in the study: Inflexal® V
(subunit influenza vaccine, Crucell Company, Berna
Biotech), SK influenza IX vaccine® (split influenza vaccine,
Fluarix®, GlaxoSmithKline). Both vaccines contained the A/
California/7/2009 (H1N1) strain (reassortant NYMC X-
181), A/Victoria/210/2009(H3N2) strain (reassortant NYMC
X-187), and B/Brisbane/60/2008 strain. The split vaccines
were allocated to 2 hospitals and the subunit vaccines were
allocated to the other 3 hospitals. Vaccines were injected into
the deltoid muscle or the upper lateral thigh either as a
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single dose or as 2 doses with a 1-month interval for un-
primed subjects younger than 9 years, as a dose of 0.25 ml
for those aged 6 months to 3 years, or as a dose of 0.5 ml for
those aged 3–18 years. We compared the immunogenicity
of the two types of influenza vaccines among the children.
Serological tests
Venous blood samples (5 ml) were collected at baseline,
1 month, and 6 months after vaccination with one or two
doses in primed or unprimed subjects depending on the
past influenza vaccination history. Anti-hemagglutinin
antibody titers were determined using the HI test accord-
ing to the WHO manual [10] using turkey erythrocytes for
A/California/7/2009 (reassortant NYMC X-181, H1N1),
and chicken erythrocytes for A/Victoria/210/2009 (reas-
sortant NYMC X-187, H3N2) and B/Brisbane/60/2008, re-
spectively. Immunogenicity was assessed according to the
seroconversion rate, seroprotection rate, and geometric
mean titer (GMT). Seroconversion was defined as a
change versus baseline titer of <1:10 to a post-vaccination
HI titer of ≥1:40 or a 4-fold or greater rise in titer in those
with an initial HI titer of ≥1:10 and it was calculated at
1 month after vaccination. Seroprotection rate was defined
as a HI titer of ≥1:40.
Statistical analysis
Descriptive data are reported as numbers of subjects and
as percentages or GMT, with 95 % confidence intervals
(95 % CI). Comparisons of immunogenicity (seroprotection
rate, seroconversion rate, GMT) among 4 groups were
performed using the one-way ANOVA. Comparison be-
tween 2 groups was performed by Student’s T-test. P value
of <0.05 was considered significant (2-tailed test). SPSS
software version 13.0 (SPSS Inc., Chicago, IL, USA) was
used for the statistical analyses.
Results
Study subjects
A total of 397 subjects were enrolled in this study, and
paired samples were obtained from 338 subjects (baseline,
1 month after vaccination) for the evaluation of immuno-
genicity. The additional blood sample at 6 months after
vaccination was taken from 283 subjects (Fig. 1). Among
the subjects in group I, 47 subjects who had a baseline
titer >1:10 were considered to have an asymptomatic
infection. They were reclassified into the final group II
(H1N1 pdm09 vaccination (-)/infection(+), n = 80). The
number of subjects in the final group I was 7. We defined
the new group II as the infection-primed (IP) group and
group III as the vaccine-primed (VP) group (Fig. 1).
Overall immunogenicity of influenza vaccines
The percentage of subjects with HI titer ≥1:40 against
H1N1 pdm09 was 56.2, 76.3, and 63.1 % at baseline,
1 month, and 6 months after vaccination, respectively.
The GMT of HI antibody against H1N1 pdm09 was
Fig. 1 Overview of the clinical study
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28.8, 78.9, and 41.6 at baseline, 1 month, and 6 months
after vaccination, respectively. The GMT-fold increase for
pH1N1 at 1 month after vaccination was 2.75 (Fig. 2).
Comparison of immunogenicity of 2010–2011 influenza
vaccines against H1N1 pdm09 between H1N1 pdm09
IP group and VP group
There was a significant difference in the seroprotection
rate at 6 months after vaccination between the two
groups (70.8 % vs 61.8 %, p = 0.032, Table 1). Serocon-
version rate was significantly higher in the IP group than
in the VP group (57.5 % vs 35.9 %, p = 0.001). GMT at
1 month after vaccination was higher in the IP group
than in the VP group (129.9 vs 66.5, p = 0.002). GMT at
6 months after vaccination was higher in the IP group
than in the VP group with no statistical significance
(54.5 vs 37.1, p = 0.150). However, mean age (10.0 yr vs
8.1 yr, p = 0.001) and split/subunit ratio (p = 0.013) were
significantly different between the two groups. When we
compared the two groups after dividing them into two
age groups (1–7 year-old group and 9–18 year-old group),
after excluding the 8-year-old subjects, there were no dif-
ferences in mean age and proportion of two vaccine types
(split vs subunit) between the IP and VP groups. In the 9–
18 year-old group (Table 2), seroconversion rate and im-
munogenicity at 1 and 6 months were significantly differ-
ent between the IP and VP groups. However in the 1–7
year-old age group, there was no significant difference be-
tween the two groups (Table 3).
Comparison of immunogenicity of split and subunit
influenza vaccines against H1N1 pdm09
In the split vaccine group which included subjects who
were 9–18 year-old, seroconversion rate, seroprotection
rate, and GMT at 1 and 6 months were significantly
higher in the IP group than in the VP group (Table 4).
In the subunit vaccine group which included subjects
who were 9–18 year-old, seroconversion rate and sero-
protection rate at 1 month were significantly higher in
the IP group than in the VP group (Table 4). Immuno-
genicity to split vaccines at 6 months after vaccination
was significantly better than that to subunit vaccines in
the VP group (% of subjects with HI antibody ≥1:40,
76.00 vs 45.68 and GMT 64.09 vs 29.05, P < 0.01).
Vaccine safety
Both vaccines were safe and no SAEs occurred. Total
solicited and unsolicited AEs were not reported differently
Fig. 2 Seroprotection rate and geometric mean titer of antihaemagglutinin anibody to H1N1 pdm09 in total subjects at base line, 1 month, and
6 months after vaccination
Table 1 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and
vaccine-primed group among the total subjects
IP (n = 80) VP (n = 228) P value
Split/subunit ratio 51/29 109/119 0.013
Mean age 8.06 (±4.28) 10.02 (±3.88) 0.001
Seroprotection (%) Baseline 58.75 (47/80) 54.82 (125/228) 0.544
1 month 80.0 (64/80) 75.00 (171/228) 0.367
6 months 70.77 (46/65) 61.86 (120/194) 0.032
Seroconversion (%) 57.5 (46/80) 35.96 (82/228) 0.001
GMT (95 % CI) Baseline 33.93 (29.80–38.05) 27.43 (24.69–30.18) 0.109
1 month 129.96 (99.18–160.74) 66.46 (58.15–72.76) 0.002
6 months 54.50 (42.32–66.67) 37.11 (33.30–40.92) 0.150
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between the split and subunit vaccine groups (65 vs 58, 11
vs 9, p > 0.05). Local AEs occurred more frequently after
administration of split vaccine (53 vs 25, p < 0.05) (Table 5).
Discussion
The present study demonstrated that previous H1N1
pdm09 natural influenza infection has superior priming
effects compared to previous H1N1 pdm09 vaccination
on immunogenicity to subsequent inactivated influenza
vaccination containing the A/California/7/2009 (H1N1)-
like strain in the 9–18 year-old group. The results of our
study are consistent with those in the study that showed
that priming by natural infection was important to elicit
a strong immune response after inactivated vaccination
in young children [11]. An animal study showed that
pigs infected with influenza virus mount an effective
immune response and are protected from subsequent
challenge, whereas the inactivated-virus vaccine does not
consistently confer complete protection to challenge
[12]. One study performed in Hong Kong showed that
children who had prior seasonal influenza infection had
significantly lower risk of subsequent pandemic influenza
infection, whereas in children who received prior seasonal
influenza vaccination, this protective effect was reduced
[13]. Cross-protection via mechanisms associated with
cell-mediated immunity has been suggested. These studies
showed that influenza virus natural infection induced
better protective immunity than inactivated influenza
vaccine.
In terms of immune responses, live-attenuated influ-
enza vaccines (LAIV) mimic natural infection. LAIV can
induce mucosal immune and cellular immune responses
[14]. From the results of the present study, we may
suppose that inactivated influenza vaccination following
live influenza vaccination will induce better immunogen-
icity than vaccination with inactivated vaccines for two
successive years. Furthermore, the possibility of down-
side of yearly vaccination with inactivated vaccines
against seasonal influenza viruses in young children was
suggested in the aspect of preventing the induction of
heterosubtypic immunity [15]. One small clinical study
performed before pandemic influenza infection in 2009
demonstrated that prime/boost combinations of LAIV
and trivalent inactivated influenza vaccine in young
children induced similar humoral responses, and regi-
mens containing LAIV induced T-cells are relevant for
heterosubtypic immunity [16]. T cells can target internal
proteins common to heterologous influenza viral strains,
Table 2 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and
vaccine-primed group in children 9-18 years of age
IP (n = 32) VP (n = 145) P value
Split/subunit ratio 17/15 57/88 0.152
Mean age 12.57 (±2.52) 12.22 (±2.22) 0.432
Seroprotection (%) Baseline 71.88 (23/32) 57.24 (83/145) 0.098
1 month 93.75 (30/32) 73.79 (107/145) 0.001
6 months 78.26 (18/23) 57.03 (73/128) 0.038
Seroconversion (%) 68.75 (22/32) 37.24 (54/145) 0.001
GMT (95 % CI) Baseline 45.55 (36.80–54.29) 29.18 (25.51–32.84) 0.041
1 month 246.75 (177.61–315.89) 69.98 (59.69–80.26) 0.000
6 months 101.81 (65.66–137.96) 39.57 (34.91–44.22) 0.001
Table 3 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and
vaccine-primed group in subjects less than 8 years of age
IP (n = 46) VP (n = 66) P value
Split/subunit ratio 32/14 44/22 0.749
Mean age 4.90 (±1.76) 5.17 (±1.77) 0.414
Seroprotection (%) Baseline 47.83 (22/46) 50.0 (33/66) 0.823
1 month 69.57 (32/46) 78.79 (52/66) 0.283
6 months 65.85 (27/41) 56.00 (28/50) 0.344
Seroconversion (%) 47.83 (22/46) 40.91 (27/66) 0.472
GMT (95 % CI) Baseline 27.03 (22.77–31.29) 24.67 (20.36–28.99) 0.620
1 month 80.00 (62.62–97.38) 61.53 (50.70–72.35) 0.392
6 months 37.38 (30.03–44.74) 31.17 (24.22–38.11) 0.481
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and cytotoxic T lymphocytes help to reduce the severity
of disease or complications [17]. Especially in children,
adequate stimulation of cellular immunity may be im-
portant for reducing severe outcomes in case of future
pandemics.
In the present study, immunogenicity to split vaccines
was significantly better than that to subunit vaccines at
6 months after vaccination in the VP group. In addition,
the priming effect induced by infection was markedly
greater in the split vaccines group than in the subunit
vaccines group in 9–18 year-old children. In our previ-
ous study, the immunogenicity of split vaccines appeared
to be better than that of subunit vaccines in unprimed
children younger than 3 years in Korea [18]. This might
be due to the difference in influenza antigens present in
the two types of vaccines, and concretely, internal virus
proteins (nucleoprotein and matrix protein) were detected
in some split vaccines [19, 20].
In a study assessing the efficacy of inactivated vaccines
against influenza A infection, efficacy was higher in the
6–15 years age group than in the 1–5 years age group
[21]. In this study, previous influenza infection was asso-
ciated with increased antibody responses to inactivated
vaccination against H1N1 pdm09 in children 9–18 years
of age than in children less than 8 years of age. Priming ef-
fect induced by previous influenza infection seemed to be
prominent in the older children. In contrast, previous vac-
cination was associated with reduced antibody responses
to inactivated influenza vaccines against seasonal influenza
A in children 9–17 years of age [22]. Both age and history
of previous vaccination or infection seemed to influence
the immunogenicity of influenza vaccination.
In this study, asymptomatic or subclinical infection was
suspected in many subjects who were not vaccinated or
infected. We initially classified only laboratory-confirmed
cases to the infection group via questionnaires, excluding
the physician’s tentative clinical diagnosis. Thus, we might
have underestimated the proportion of infected subjects.
Table 4 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and
vaccine-primed group in the split and subunit vaccine group among children 9-18 years of age
IP (n = 32) VP (n = 145) P value
Split 17 57
Mean age 12.81 (±2.44) 11.76 (±2.01) 0.077
Seroprotection (%) Baseline 70.59 (12/17) 52.63 (30/57) 0.098
1 month 94.12 (16/17) 75.44 (43/57) 0.001
6 months 86.67 (13/15) 76.00 (38/50) 0.038
Seroconversion (%) 64.71 (11/17) 38.60 (22/57) 0.001
GMT (95 % CI) Baseline 35.39 (26.93–43.86) 30.61 (23.99–37.24) 0.644
1 month 250.56 (138.16–362.95) 77.13 (66.37–87.90) 0.004
6 months 139.29 (94.10–184.47) 64.09 (53.03–75.14) 0.019
Subunit 15 88
Mean age 12.30 (±2.67) 12.74 (±2.57) 0.544
Seroprotection (%) Baseline 73.33 (11/15) 60.23 (53/88) 0.345
1 month 93.33 (14/15) 73.86 (65/88) 0.022
6 months 62.5 (5/8) 45.68 (37/81) 0.369
Seroconversion (%) 73.33 (11/15) 37.50 (33/88) 0.011
GMT (95 % CI) Baseline 60.63 (36.22–85.04) 28.28 (23.98–32.59) 0.015
1 month 242.51 (158.95–326.08) 65.70 (51.58–79.82) 0.002
6 months 56.57 (10.48–102.66) 29.05 (23.28–34.82) 0.166
Table 5 Incidence of adverse events (AEs) during the first












Fever/chill 3 9 0.094
Headache 1 7 0.038
Myalgia 6 13 0.12




Pain 31 14 0.004
Erythema 5 2 0.23
Swelling 9 9 0.92
Unsolicited AE 11 9 0.57
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Therefore, among the subjects in group I, we reclassified
47 subjects who had a baseline HI titer > 1:10 and who
were not vaccinated or infected into group II. They were
considered to have an infection because they did not have
preexisting cross-reactive antibodies [23]. Among subjects
in the vaccination (+)/infection (-) group, there might be a
possibility of an asymptomatic infection.
There are several limitations to this study. First, there is
some possibility of inaccurate information obtained from
the questionnaire about previous H1N1 pdm09 infection
and vaccination. However, memory error is less likely
because novel pandemic H1N1 influenza in Korea was a
hot issue at that time especially among caregivers. An-
other limitation is that we did not investigate the history
of taking oseltamivir among the children who had natural
infection. Oseltamivir treatment may reduce the viral load
of patients with infection [24] and may negatively influ-
ence the immune response against the influenza virus.
Conclusions
In conclusion, previous H1N1 pdm09 natural infection
had a superior priming effect on immunogenicity to sub-
sequent inactivated influenza vaccination in the 9–18
year-old age group. We can suppose that initial live at-
tenuated vaccines may induce a more effective immune
response to subsequent inactivated vaccines in unprimed
children.
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